Company Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:23 2024-07-19 am EDT 5-day change 1st Jan Change
12.9 GBX -1.90% Intraday chart for Poolbeg Pharma PLC -4.80% +42.54%

Business Summary

Poolbeg Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The Company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases.

Number of employees: 15

Managers

Managers TitleAgeSince
Chief Executive Officer 53 21-04-30
Director of Finance/CFO 37 20-12-31
Investor Relations Contact - 20-12-31
General Counsel - 22-06-30
General Counsel 37 Dec. 31
Corporate Officer/Principal 54 Nov. 30
Comptroller/Controller/Auditor - 21-05-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 60 -
Chief Executive Officer 53 21-04-30
Founder 59 20-08-31
Director/Board Member 73 23-05-23
Director of Finance/CFO 37 20-12-31
Director/Board Member 50 21-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 500,000,000 378,090,775 ( 75.62 %) 0 75.62 %

Shareholders

NameEquities%Valuation
37,219,757 7.444 % 6 M p
26,039,455 5.208 % 4 M p
Schroder Investment Management Ltd.
4.999 %
24,994,777 4.999 % 4 M p
Hygea VCT Plc (Private Equity)
1.470 %
7,348,028 1.470 % 1 M p
Gresham House Asset Management Ltd.
0.8491 %
4,245,376 0.8491 % 697 643 p
873,497 0.1747 % 143 542 p

Company contact information

Poolbeg Pharma Plc

Queen Mary BioEnterprises Innovation Centre

E1 2AX, London

+

http://www.poolbegpharma.com
address Poolbeg Pharma PLC(POLB)

Sales per region

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.129 GBP
Average target price
0.21 GBP
Spread / Average Target
+62.79%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. POLB Stock
  4. Company Poolbeg Pharma PLC